Bictegravir-Induced Drug Reaction With Eosinophilia and Systemic Symptoms in a Patient With Acute Human Immunodeficiency Virus

Madeline A DiLorenzo; Nicola Medrano; Jason N Chen; Fatima Bawany; Duy C Tran; Pulkit Taunk; Shane A Meehan; Miriam Keltz Pomeranz; Ofole Mgbako

doi:10.1093/ofid/ofad066

Bictegravir-Induced Drug Reaction With Eosinophilia and Systemic Symptoms in a Patient With Acute Human Immunodeficiency Virus

Open Forum Infect Dis. 2023 Feb 8;10(3):ofad066. doi: 10.1093/ofid/ofad066. eCollection 2023 Mar.

Authors

Madeline A DiLorenzo¹, Nicola Medrano¹, Jason N Chen², Fatima Bawany³, Duy C Tran³, Pulkit Taunk², Shane A Meehan⁴, Miriam Keltz Pomeranz³, Ofole Mgbako¹

Affiliations

¹ Division of Infectious Diseases and Immunology, Department of Medicine, NYU Langone Health, New York, New York, USA.
² Department of Internal Medicine, NYU Langone Health, New York, New York, USA.
³ Ronald O. Perelman Department of Dermatology, NYU Langone Health, New York, New York, USA.
⁴ Department of Pathology, NYU Langone Health, New York, New York, USA.

Abstract

Although drug reaction with eosinophilia and systemic symptoms (DRESS) is associated with antiretrovirals, there are no published reports of bictegravir-induced DRESS. Bictegravir is recommended as first-line treatment for patients with human immunodeficiency virus (HIV). Recognition of DRESS, its skin manifestations, and potential complications is vital for appropriate care and management of acute HIV.

Keywords: DRESS; HIV; antiretroviral therapy; bictegravir; drug reaction with eosinophilia and systemic symptoms.